Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Other Operating Expenses (2016 - 2025)

Guided Therapeutics' Other Operating Expenses history spans 15 years, with the latest figure at $22000.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses fell 71.05% year-over-year to $22000.0; the TTM value through Sep 2025 reached $214000.0, down 24.65%, while the annual FY2024 figure was $287000.0, 7.09% up from the prior year.
  • Other Operating Expenses for Q3 2025 was $22000.0 at Guided Therapeutics, down from $50000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $76000.0 in Q3 2024 and bottomed at -$1000.0 in Q2 2022.
  • The 5-year median for Other Operating Expenses is $53000.0 (2022), against an average of $51684.2.
  • The largest annual shift saw Other Operating Expenses plummeted 103.7% in 2022 before it skyrocketed 6100.0% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $34000.0 in 2021, then skyrocketed by 55.88% to $53000.0 in 2022, then increased by 24.53% to $66000.0 in 2023, then grew by 4.55% to $69000.0 in 2024, then tumbled by 68.12% to $22000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Other Operating Expenses are $22000.0 (Q3 2025), $50000.0 (Q2 2025), and $73000.0 (Q1 2025).